Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials

Movement Disorders

Volumn 26, Issue 8, 2011, Pages 1464-1476

  Sampaio, Cristina ^a   Bronzova, Juliana ^b   Hauser, Robert A ^c   Lang, Anthony E ^d   Rascol, Olivier ^e   van de Witte, Serge V ^b   Theeuwes, Ad ^b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Pardoprunox (SLV308); Parkinson's disease; Partial dopamine agonist; Randomized controlled trial

Indexed keywords

AMANTADINE; PARDOPRUNOX; PLACEBO; PRAMIPEXOLE; RASAGILINE; SELEGILINE;

ADULT; ANXIETY DISORDER; ARTICLE; ASTHENIA; BACKACHE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER ABDOMINAL PAIN; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

AGED; ANTIPARASITIC AGENTS; BENZOXAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PIPERAZINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960573428     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23590     Document Type: Article

References (17)

1. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Ann Rev Neurosci. 1999; 22: 123-144.
2. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc J-L. Limitations of current Parkinson's disease therapy. Ann Neurol. 2003; 53( Suppl 3): S3-S15.
3. McCreary AC, Ronken E, van der Heyden J, et al. SLV308: a novel antiparkinsonian agent with antidepressant and anxiolytic properties. In: Ronken E, van Scharrenburg GJM, eds. Parkinson's Disease (Solvay Pharmaceutical Research Symposium). Amsterdam, The Netherlands: IOS Press; 2002: 51-58.
4. Johnston LC, Rose S, McCreary AC, Jackson M, Hesselink M, Jenner PJ. Full (ropinirole) and partial (SLV308) dopamine agonists and the relationship to dyskinesia priming in MPTP-treated marmosets. Mov Disord. 2005; 20( S10): P16. Poster.
5. Bronzova J, Sampaio C, Hauser RA, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord. 2010; 25: 730-738.
6. Hauser RA, Bronzova J, Sampaio C, et al. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. Eur Neurol. 2009; 62: 40-48.
7. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl. 1993; 39: 165-172.
8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967; 17: 427-442.
9. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995; 4: 241-248.
10. Adler CH, Sethi KD, Hauser RA, et al., for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49( 2): 393-399.
11. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000; 284: 1931-1938.
12. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007; 64: 676-682.
13. Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M. Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa. Neurology. 1987; 37: 863-865.
14. Ruggieri S, Stocchi F, Baronti F, et al. Antagonistic effect of terguride in Parkinson's disease. Clin Neuropharmacol. 1991; 14: 450-456.
15. Verhagen Metman L, Sethy VH, Roberts JR, et al. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Mov Disord. 1994; 9: 577-581.
16. 1A receptor agonist. Synapse. 2006; 60: 599-608.
17. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci. 2006; 248: 151-157.